Precision Acquires Precision Health Economics – PharmaVoice
Precision for Medicine’s acquisition of Precision Health Economics is covered in PharmaVoice.
New Push Ties Cost of Drugs to How Well They Work – The Wall Street Journal
Precision for Medicine’s Larry Blandford quoted in today’s Wall Street Journal article: “New Push Ties Cost of Drugs to How Well They Work.” The effort is part of a growing push for so-called pay-for-performance deals amid complaints about the rising price of medications, some of which cost more than $100,000 per patient a year.
Commentary: Aligning Incentives to Fulfill the Promise of Personalized Medicine
Precision’s Dana Goldman and Senior Research Economist Karen Van Nuys, along with co-authors Victor J Dzau, Geoffrey S Ginsburg and David Agus, address new developments in personalized medicine.
Commentary: Non-Adherence in Healthcare: Are Patients or Policymakers Ill-Informed?
Precision’s Tomas Philipson in his regular column in Forbes.com, talks about the precision medicine initiative as a more useful approach towards appropriate adherence behavior.
Exploring Precision Medicine’s Value – Managed Healthcare Executive
In the May cover story: “Exploring Precision Medicine’s Value” Dan Renick discusses the value of specialized treatments. He contends that precision medicine in the face of limited resources necessitates evidence generation that supports the value of therapeutic breakthroughs. The in-depth article explores the value of precision medicine from a research, governmental and managed care perspective